Vishnupriya
New Delhi: Global medical device maker Abbott has introduced the Navitor Vision in India, a state-of-the-art valve technology for treating symptomatic severe aortic stenosis in patients who face high or extreme risk from conventional surgery.
The Navitor Vision represents the latest advancement in Abbott’s transcatheter aortic valve implantation/replacement (TAVI/TAVR) system. Its innovative design incorporates enhanced markers, which assist interventionists in implanting the valve with greater precision and provide improved visibility during the procedure, the company announced.
TAVI, a groundbreaking, minimally invasive procedure, allows for the replacement of a damaged aortic valve through small incisions, often in the groin. This approach reduces recovery time and lowers risks compared to traditional open-heart surgery, the statement added.
Speaking about the launch, Neeraj Singh from Abbott’s structural heart division in India, said, “TAVI serves as a less invasive alternative to surgical aortic valve replacement, reducing symptoms and improving life expectancy for patients. Abbott’s Navitor Vision valve is a significant addition to our portfolio for structural heart treatments, particularly for heart valve diseases, offering hope to patients who may have limited treatment options.”
Aortic stenosis, a severe and life-threatening condition, occurs when the aortic valve narrows, restricting blood flow from the heart to the rest of the body. If left untreated, it can lead to heart failure, impaired quality of life, and, in some cases, sudden cardiac death.
By bringing the Navitor Vision to India, Abbott aims to improve outcomes for patients with symptomatic severe aortic stenosis while expanding access to innovative, life-saving technologies.
